Tonix Advances TNX-102 SL Into Phase 2 Depression Trial, Drawing Investor Focus
TipRanks (Tue, 2-Jun 12:31 PM ET)
Alliance Global Partners Sticks to Their Buy Rating for Tonix Pharma (TNXP)
TipRanks (Mon, 1-Jun 8:48 AM ET)
Globe Newswire (Thu, 28-May 4:30 PM ET)
Globe Newswire (Wed, 27-May 7:00 AM ET)
Globe Newswire (Tue, 26-May 7:00 AM ET)
Globe Newswire (Thu, 14-May 7:00 AM ET)
Tonix Pharmaceuticals to Participate in Two Investor Conferences in May
Globe Newswire (Tue, 12-May 4:30 PM ET)
Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights
Globe Newswire (Mon, 11-May 4:30 PM ET)
Tonix’s TONMYA Gains Key Commercial Coverage—Opening Access for 35 Million Fibromyalgia Patients
Market Chameleon (Wed, 6-May 4:14 AM ET)
Globe Newswire (Wed, 6-May 7:00 AM ET)
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Tonix Pharmaceuticals Holding Corp. trades on the NASDAQ stock market under the symbol TNXP.
As of June 5, 2026, TNXP stock price declined to $11.16 with 272,835 million shares trading.
TNXP has a beta of 2.56, meaning it tends to be more sensitive to market movements. TNXP has a correlation of 0.12 to the broad based SPY ETF.
TNXP has a market cap of $177.90 million. This is considered a Micro Cap stock.
Last quarter Tonix Pharmaceuticals Holding Corp. reported $7 million in Revenue and -$2.93 earnings per share. This fell short of revenue expectation by $-542,000 and missed earnings estimates by -$.42.
In the last 3 years, TNXP traded as high as $6,719.68 and as low as $6.76.
The top ETF exchange traded funds that TNXP belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
TNXP has underperformed the market in the last year with a price return of -71.3% while the SPY ETF gained +26.1%. TNXP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -20.2% and -20.3%, respectively, while the SPY returned +8.9% and +0.2%, respectively.
TNXP support price is $11.21 and resistance is $12.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TNXP shares will trade within this expected range on the day.